AlMalek Trading & Import Launches New Antibiotic in the Yemeni Market

Sana’a –18 September 2025
AlMalek Trading & Import, one of the leading companies in pharmaceutical import and distribution, has announced the launch of a new drug in the Yemeni market under the brand name Herovanz 1g (Ertapenem), a next-generation antibiotic administered once daily. The product aims to enhance treatment options for physicians and pharmacists in managing complicated bacterial infections, offering advanced selectivity that helps prevent bacterial resistance while ensuring safe and effective therapy.

The announcement was made during a scientific introduction event organized by the company at Shahran Hotel in Sana’a and Al-Thawra General Hospital, with the participation of a group of physicians, pharmacists, and healthcare professionals. The event highlighted the critical role of antibiotics in addressing current medical challenges, with a particular focus on the clinical advantages of Herovanz as one of the latest pharmaceutical innovations in this field.
The scientific program featured a series of presentations and interactive discussions delivered by specialists in infectious diseases and clinical pharmacy. Experts reviewed key studies and clinical experiences demonstrating the drug’s effectiveness in controlling complex bacterial infections, while emphasizing its convenience through a once-daily dosage regimen.

In her remarks, AlMalek Trading & Import reaffirmed its strong commitment to delivering innovative therapeutic solutions that support modern healthcare practices and respond to the growing needs of the Yemeni market. The company stressed that the launch of Herovanz represents a significant step forward in strengthening the local healthcare sector and equipping medical professionals with advanced tools to combat pressing health challenges.
The introduction of this new antibiotic comes at a time of increasing demand for reliable treatments capable of addressing evolving patterns of antimicrobial resistance. This positions Herovanz as a valuable addition to the Yemeni pharmaceutical market, particularly in hospitals and medical centers handling critical and complicated cases.

The company concluded the event by emphasizing its ongoing plans to organize scientific and educational programs targeting doctors and pharmacists. These initiatives are designed to foster professional exchange and ensure the Yemeni medical community has access to the latest pharmaceutical innovations—ultimately enhancing the quality of healthcare services provided to patients nationwide.